# TIMELINE — John P. Frawley, 1948–2007

Interleaves (▪ pub) Frawley's publications · (◆ deminimis) the threshold proposal & FDA reaction ·
(☣ dioxin) the inter-company dioxin/herbicide events · (⚖ lit) the litigation. Tags: **[P]** primary,
**[2]** secondary, **[abs]** absence-of-evidence. Dates in **bold** are documented to the day.

The point of laying these side by side: Frawley's **1983 sworn knowledge account** can be read against
his **own contemporaneous 1960s record**. Watch the 1963–1965 rows.

---

### FDA era (Division of Pharmacology)

- *(lineage root — radiation, pre-Frawley)* **1946/1954** ◆[P] **Lea, *Actions of Radiations on Living Cells*** (single-hit **target theory** — gene mutation "due to a single ionization," threshold-free; register H31) → **NBS Handbook 59 / NCRP-17 (1954)** draws the policy consequence: "**no threshold dose for the production of gene mutations… no such thing as a tolerance dose**," replacing "tolerance dose" with a "permissible dose" set by "**readily acceptable**" risk (register H29). *The headwater of "acceptable risk," later transplanted into chemical-carcinogen 10⁻⁶.* [`sources/Lea1946…`, `sources/NBS-Handbook59_1954…`]
- **1950** ▪[P] Fitzhugh, Nelson & Frawley, chronic toxicity of benzene hexachloride, *JPET* 100(1):59–66 — earliest located Frawley paper.
- **1951** ▪[P] Fitzhugh, Nelson & Frawley, "A Comparison of the Chronic Toxicities of Synthetic Sweetening Agents," *J. Am. Pharm. Assoc.* 40(11):583–586 (saccharin, cyclamate, dulcin) — the identity-anchor paper.
- **1952** ▪[P] Frawley, Hagan & Fitzhugh, organophosphate–anticholinesterase study, *JPET* 105(2):156–165.
- **1953** ☣/▪ **[disambiguation-contested]** A "John P. Frawley, 1st Lt., Medical Service Corps" serves on the **46th MASH** Surgical Research Team in Korea (with Howard & Artz). Frawley's *toxicology* publication record shows a **1953–55 gap** that coincides with this window — consistent with, but **not proof of**, the FDA toxicologist and the MASH officer being the same man. *Two workflow agents reached opposite conclusions; treated as OPEN.*
- **1957** ▪[P] Frawley, Fuyat, Hagan, Blake & Fitzhugh, "**Marked potentiation in mammalian toxicity from simultaneous administration of two anticholinesterase compounds**" (malathion–EPN synergism), *JPET* 121(1):96–106 — his FDA-era classic.

### Transition to Hercules

- **c. 1956** ⚖[P] Per his 1983 deposition (recited at 565 F. Supp. at 1273), Frawley "**has been with Hercules since 1956.**" (Note the partial overlap with late FDA-coauthored papers through 1958–59 — typical of a staged move.)
- **1958** ◆[P] Congress passes the Food Additives Amendment; rosin is swept in as (per Frawley) a "poisonous and deleterious substance," forcing 2-year studies on Hercules' food-grade rosins.
- **1959** ▪[P] Fitzhugh, Bourke, Nelson & Frawley, stearic-acid emulsifiers, *Toxicol. Appl. Pharmacol.* 1(3):315–331 (inaugural TAP volume).

### The rosin program → the de minimis idea (commercial driver)

- **1961** ⚖[P] Hercules buys the **Jacksonville, Arkansas** plant (later Vertac). [Encyclopedia of Arkansas / EPA]
- **28 Feb–1 Mar 1961** ◆[P] **HR 3980 hearing** (House Interstate & Foreign Commerce) on extending the 1958 Food Additives Amendment grace period — the **Delaney/Dingell two-pole framing on one record**: Delaney resists "open end" extension ("the law… [must] be **strengthened rather than relaxed**… an open end bill would be a retreat"); Dingell works timelines with Commissioner Larrick. *Lineage context — register H28.* [`sources/HR3980-hearing-1961_Delaney-Dingell_excerpt.md`]
- **1963** ▪[P] Frawley, Weir, Tusing, DuBois & **Calandra** (IBT president), "Toxicologic investigations on Delnav," *TAP* 5:605–624 — **first IBT-linked co-authorship** (COI thread begins).
- **3 Jul 1963** ☣ **[DOC A]** Frawley writes **V.K. Rowe (Dow)** re USDA Dr. John Leary's request to test phenoxy herbicides. Per Frawley's 1983 affidavit, the health-hazard items concerned **2,4-D, not 2,4,5-T.** *Primary scan never located (absence).* ⟵ **compare to 1983 sworn account**
- **Oct 19–20 1964** ▪[P] Frawley delivers the **rosin safety paper** at the Naval Stores Work Conference (publ. 1965): >70 Hercules rosin products, 34 studied, studies "**conducted under contract by the Industrial Bio-Test Laboratories**"; ~5,000 rats + 138 dogs; the $50k-per-compound cost is the explicit motive for a de minimis exemption.
- **19 Dec 1964** ☣[P-cite] Boehringer Ingelheim warns Dow the "extraordinary danger" of the dioxin "is not generally known." [Poison Papers 1A-1-563]

### 1965 — the pivotal dioxin year

- **Feb 1965** ☣/⚖[P] Per Frawley's 1983 affidavit: his "**first knowledge… of industrial health problems associated with the production of 2,4,5-T occurred in February 1965, when he was told by Dow of its chloracne problem**"; he says he did **not** learn of Monsanto's **1949 Nitro** chloracne until then.
- **19 Mar 1965** ☣ **[P — CROWN-JEWEL DOCUMENT]** **V.K. Rowe (Dow) letter to "Dr. John P. Frawley, Hercules Powder Company"** (+ Monsanto's Emmet Kelly, Hooker, Diamond Alkali) convening a meeting on "highly toxic impurities" in 2,4,5-trichlorophenol. **Poison Papers Bates B 1575 · DocumentCloud 3253794.**
- **24 Mar 1965** ☣[2/⚖P] Frawley **attends the Dow "Chloracne Problem Meeting"** (Midland; Dow, Diamond Alkali, Hooker, Hercules); receives Dow's analyses showing Hercules' product had "**a very low level of dioxin**" (565 F. Supp. at 1273). A Hercules memo of the meeting (Poison Papers) records Dow "fearful of a congressional investigation"; Hercules: PHS "happy to get in the act." **[DOC B is most likely a paraphrase of this memo + C3 below.]**
- **24 Jun 1965** ☣[2] **V.K. Rowe (Dow) → Ross Milholland**: dioxin "exceptionally toxic… chloracne and systemic injury"; whole 2,4,5-T industry would be "hard hit" by restrictive legislation; "**Under no circumstances may this letter be reproduced… outside of Dow.**"
- **later 1965** ⚖[P] Hercules improves its 2,4,5-T process and begins testing its own product for dioxin (per affidavit).
- **1965** ▪[P] Two IBT/Calandra **BHT** papers (*FCT* 3:377–386; 3:471–474) and two FCT opinion pieces ("Our sacred food"; "Suds and sensitivity").

### The de minimis proposal goes public

- **14 Sep 1966** ◆[2] At the **152nd ACS National Meeting, New York**, Frawley first publicly advances the **0.2% / <0.1 ppm "toxicologically insignificant"** exemption (carve-outs for carcinogens, pesticides, heavy metals, and anything toxic ≤40 ppm); companion attack-on-FDA paper by packaging attorney **Jerome H. Heckman**. (Frawley's data base: 143 chronic studies.) [Keller & Heckman history]
- **1966** ▪[P] Kinoshita, Frawley & DuBois, DDT/**toxaphene** microsomal-enzyme induction, *TAP* 9:505–513 (toxaphene = a Hercules product).
- **25 Jan 1967** ◆[P] Frawley delivers the mature version at the **BIBRA Fifth Annual Scientific Meeting, London** (220 chronic studies), published as *Food Cosmet. Toxicol.* 5(3):293–308. States FDA "**authorized me to tell you that they are giving it serious consideration, but could not reach a decision prior to this meeting.**" Appendix cites unpublished **Hercules** (ref. 3) and **IBT** (ref. 26) data.
- **1967–68** ◆[P-cite] Frawley corresponds with the **NAS Food Protection Committee** (letters to Paul Johnson, the FDA Hearing Clerk, Richard Hall) — UCSF Darby Papers.
- **13 Feb 1968** ◆[P] FDA's **National Conference on Indirect Food Additives** (Washington D.C.; opened by Commissioner Goddard) — the agency's response to Rep. Dingell's unanswered Aug-1967 questions. **Frawley presents his "Reasoned Approach"** address (245 chronic studies; 0.1 ppm / 0.2% rule; "24 toxicologists endorsed it to FDA"; "I personally had spent over a million dollars… all wasted"), printed as *Food Drug Cosm. Law J.* 23(5):260–270. **FDA Bureau of Science chief W. H. Summerson rebuts it** the same day — "soundness… but… sheer nonsense" (*Food Chem. News*, 19 Feb 1968). [Frawley's text = local PDF; Summerson = `08_VINYL_CHLORIDE` §4]
- **12 Jul 1968** ◆[P-cite] Frawley writes the NAS **"Ad Hoc Committee on Insignificant Levels"** that he will **not** take an active part in drafting its report. [UCSF **yhgd0228**]
- **1968** ▪[P] (the **Fitzhugh tribute**, *FCT* 6(2):121–122; Frawley's "Reasoned Approach" FDCLJ paper is now dated above to the 13 Feb 1968 conference.)
- **1969** ◆[P] The NAS/NRC Food Protection Committee publishes "**Guidelines for Estimating Toxicologically Insignificant Levels of Chemicals in Food**" (now read in full, local PDF): builds on the **1/100** no-adverse-effect factor; recommends **0.1 ppm** insignificance for established commercial chemicals (Frawley's exact number) + **1.0 ppm** by structural analogy; cites Frawley 1967; **drafting Task Force includes J.P. Frawley** (Smyth chair; Coon, Hall, Oser, Schramm, Zapp). DOI 10.17226/20376. *The idea Summerson called "sheer nonsense" in Feb 1968 is NAS-recommended within a year.*
- **1969** ◆[2] FDA's "serious consideration" crystallizes as the **Ramsey Proposal** (≤50 ppb migration exemption).
- **Aug 1968 / released 1969** ☣[P] Per affidavit, Hercules learns of possible 2,4,5-T **teratogenicity** only when the government releases the **Bionetics Report** (commissioned 1963).

### Regulatory fights & winding down

- **Apr 7 & 15 1970** ⚖[P] Senate "**Effects of 2,4,5-T on Man and the Environment**" hearings — **Frawley absent** from the witness index (Dow's Rowe testifies). [read directly]
- **3 Jun 1971** ◆[2] FDA tells Ramsey it cannot go forward with his proposal — "scientifically sound" but legally unworkable. *The de minimis idea dies inside FDA for a generation.* *(The statutory authority FDA believes it lacks here is granted by the courts in **1979** — see Monsanto v. Kennedy below.)*
- **4 Mar 1971** ☣[P-cite] Frawley & **E. Ross Hart** (Hercules) → EPA/USDA's **Upholt** re the Bionetics 2,4,5-T study. [UCSF **rxfb0228**]; **5 May 1971** the 2,4,5-T Advisory Committee "Objections" doc names Frawley + Hercules [UCSF **zkcb0228**].
- **1971** ▪[P] Su, Kinoshita, Frawley & DuBois (18 organophosphates), *TAP* 20:241–249; Borzelleca, …, Frawley, …, Hayes, McCollister & Scala letter, *Science* 174:545–546.
- **1973** ▪[P] Kennedy, Frawley & **Calandra** (IBT), multigeneration pesticide reproduction, *TAP* 25(4):589–596 — the last and most IBT-entangled study (the kind later central to the IBT fraud findings). *(A secondary source renders a co-author "Frawley MP"; PMID 4795382 gives JP.)*
- *(lineage — the 10⁻⁶ written down)* **1973 → 1977 → 1979** ◆[P] **FDA's DES "Sensitivity of the Method" rulemakings** (register **H32**), where the carcinogen "acceptable risk" number was chosen in the open: **38 FR 19226 (19 Jul 1973)** sets it at **1/100,000,000 (10⁻⁸, Mantel-Bryan)**, "**an arbitrary but conservative level**"; **42 FR 10412 (22 Feb 1977) final rule moves it up to "1 in 1 million"** ("of insignificant public health concern"); **44 FR 17070 (20 Mar 1979) §8** defends the move — 10⁻⁸ was "**unduly limiting without substantial compensation in terms of public health**," the number to "**be as high as possible in order to permit the use of carcinogenic animal drugs**." *Dates & corroborates the Hutt account (H1); → final 52 FR 49572 (1987).* [`sources/SOM-DES_1973-1979_10-8-to-10-6_origin_excerpt.md`]
- *(lineage bridge)* **1976** ◆[P] **Crump, Hoel, Langley & Peto, "Fundamental Carcinogenic Processes…"** (*Cancer Res.* 36:2973) — the **linear-at-low-dose** method bridge that retired Mantel-Bryan probit and seeded EPA's no-threshold default; names the radiation precedent ("**as it was for radiation 20 years ago**") and concedes (footnote 3) that 10⁻⁶ vs 10⁻⁸ has "**no compelling reason**." *Register H26.* [`sources/CrumpHoelLangleyPeto1976…`]

### Late career, litigation, legacy

- **6 Nov 1979** ◆⚖[P] ***Monsanto Co. v. Kennedy*, 613 F.2d 947 (D.C. Cir.)** (Leventhal, J.) — the D.C. Circuit holds the FDA Commissioner **may decline to treat a migrant as a "food additive"** where its level is "**so negligible as to present no public health or safety concerns**" — the **de minimis authority** FDA thought it lacked in 1971. **Co-petitioner: the Society of the Plastics Industry**, the same trade group that ran Frawley's 1967–68 campaign. *This is the legal authority the 1995 rule is built on.* [60 FR at 36584; `10_DE_MINIMIS_LEGAL_LINEAGE.md`]
- **Jun 1981** ▪[P] Frawley, "**The 1980s — A decade of change**," *Regul. Toxicol. Pharmacol.* 1(1):3–7 — the inaugural-issue article (he is an associate editor).
- **May 1982 → 14 Oct 1982** ⚖[2] Special Master **Schreiber's PTO 43 / 96 F.R.D. 582** seals all MDL 381 documents and depositions (Frawley's among them).
- **20 May 1983** ⚖[P] **565 F. Supp. 1263**: Judge **Pratt** grants **Hercules summary judgment** on the government-contractor defense, resting on **Frawley's deposition + affidavit** (dioxin-free product; no worker chloracne 1961–70; first knowledge Feb 1965; the 1963 letter "relate[s] to 2,4-D, not… 2,4,5-T"). Rearg. denied **22 Jun 1983**.
- **(post-1983)** ⚖[2] **Chief Judge Weinstein WITHDRAWS Pratt's opinion** and reinstates the defendants — the SJ win is **vacated before trial.** [recited in 516 U.S. 417]
- **May 1984** ⚖[P] Hours before trial, defendants create the **$180M** settlement fund; **Hercules' share = $18,772,568.**
- **1985** ▪[P] Frawley, "Editorial," *RTP* 5(3):239.
- **1987** ▪[P/◆] **Rulis (FDA)** publishes "De Minimis and the Threshold of Regulation," **crediting Frawley 1967** as precursor. Same year, SOT gives Frawley the **Arnold J. Lehman Award** (named for his own FDA mentor/co-author).
- **23 Oct 1987** ◆⚖[P] ***Public Citizen v. Young*, 831 F.2d 1108 (D.C. Cir.)** (Williams, J.) — the de minimis doctrine **stops at the Delaney line**: no trivial-risk exception for a carcinogen, even at "**one in 19 billion**" (Orange No. 17). *The same year Rulis revives Frawley's number, the courts cap de minimis exactly where Frawley himself drew the carcinogen carve-out.* [`10_DE_MINIMIS_LEGAL_LINEAGE.md`]
- **1987** ⚖[P-cite] *U.S. v. Vertac*, 671 F. Supp. 595 cites "**Frawley deposition p. 45**" (PX 213) — a second deposition appearance.
- **31 Dec 1987** ◆[P] FDA's **"Sensitivity of the Method" final rule, 52 FR 49572** (21 CFR 500 Subpart E) — the **carcinogen-side 10⁻⁶ written into law**: "no residue" given an "operational definition" = the dose at "a maximum lifetime risk… **on the order of 1 in 1 million**," reached *not* by de minimis but inside the DES Proviso; records 10⁻⁶ as an adopted consensus that must be "high enough to permit the use of carcinogenic animal drugs." *The Hutt redefinition, now in the rule's own words — register H25.* [`10` §3.5; `sources/FDA_SOM-rule_52FR49572_1987_no-residue-10-6_excerpt.md`]
- **1988–90** ▪[2] Frawley is **ISRTP** VP then **president** (W. Gary Flamm as VP); runs **Health & Environment International Ltd.**, Wilmington.
- **1989** ▪[P] Frawley reprises "**Our sacred food — a perspective**," *RTP* 9(3):209–211. Same *RTP* volume: **Mary Frances Lowe (FDA)**, "Risk Assessment and the Credibility of Federal Regulatory Policy: An FDA Perspective," *RTP* 9:131–141 — FDA's open defense of "a common sense **de minimis interpretation of the 'Delaney clause'**," narrating *Public Citizen v. Young*. *Frawley's argument in the agency's mouth — register H27.* [`sources/Lowe1989_FDA-de-minimis-Delaney-defense_excerpt.md`]
- **8 Jul 1992** ◆⚖[P] ***Les v. Reilly*, 968 F.2d 985 (9th Cir.)** (Schroeder, J.) — extends the no-de-minimis-under-Delaney rule to **pesticide** residues in processed food; EPA's negligible-risk theory (built on the NAS 1987 *Regulating Pesticides in Food: The Delaney Paradox*) is **set aside**. [`10_DE_MINIMIS_LEGAL_LINEAGE.md`]
- **Mar–Apr 1994** ⚖/▪[P] A **"Statement of John P. Frawley, Ph.D."** is **drafted** (by/with **Covington
  & Burling**) for the House **Waxman tobacco hearings** — Frawley as a **tobacco-industry consultant** —
  but is a DRAFT **never delivered** (zero "Frawley" in the printed record). [UCSF IDL zqxb0104, lhyg0018, …]
- **1996** ⚖[P] **Hercules, Inc. v. United States**, 516 U.S. 417 — Supreme Court denies Hercules recovery of its settlement/defense costs from the U.S.
- **1996** ◆[P] **NRC, *Carcinogens and Anticarcinogens in the Human Diet*** (NAP 5150) — the **NAS "same yardstick"**: grants Ames's mechanistic premise ("no clear difference between the potency of… naturally occurring and synthetic carcinogens") but **declines the de minimis conclusion** (gaps; risk implications "controversial"). *The 1969-Guidelines move repeated — yardstick blessed, trifle withheld; register H30.* [`sources/NRC1996_same-yardstick_excerpt.md`]
- **17 Jul 1995** ◆[P] FDA's **Threshold of Regulation rule (21 CFR 170.39, 60 FR 36582)** — the de minimis idea finally codified (0.5 ppb), via the **Rulis** line; the rule cites Rulis, **not Frawley** directly. The preamble **rests the rule on *Monsanto*'s de minimis authority**, recites the maxim *de minimis non curat lex*, and (per *Public Citizen v. Young*) **conditions the exemption on the substance not being a carcinogen** — Frawley's own carve-out, now law. [`10_DE_MINIMIS_LEGAL_LINEAGE.md`]
- **~2003–2004** Frawley **dies** (bracketed by SOT deceased-asterisk convention; exact date **unconfirmed**, no obituary located).
- **1998 / 2007** ⚖[2] Hercules pays **$102.9M (1998)** and **$124M (2007)** Vertac-site Superfund judgments — the long tail of the Jacksonville 2,4,5-T/dioxin operation.

---
*The 1963–1965 cluster is the analytic heart: see **06_ANALYTIC_MEMO** for the consistency assessment of
Frawley's 1983 sworn account against these contemporaneous rows.*